Higher incidence of injection site reactions after subcutaneous bortezomib administration on the thigh compared with the abdomen

Tomohiko Kamimura, Toshihiro Miyamoto, Noriko Yokota, Shuichiro Takashima, Yong Jeong, Yoshikiyo Ito, Koichi Akashi

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Subcutaneous (sc) rather than intravenous administration of bortezomib (Bor) is becoming more common for treating multiple myeloma (MM) because scBor results in lower incidence and severity of peripheral neuropathy and has equivalent efficacy. Bor is an irritant cytotoxic agent when it leaks out; therefore, it is recommended that injections of scBor should be rotated among eight different sites on the abdomen and thigh. However, detailed information about injection site reaction (ISR) has not been sufficiently documented. We retrospectively analyzed the incidence and severity of ISR following scBor administration in 15 Japanese patients with MM. Grade 1 ISR occurred following 40 of 158 (25.3%) scBor injections in ten patients, whereas grade 2 ISRs occurred following seven injections (4.4%) in five patients. Five patients did not develop ISR. Of note, grade 2 ISR was documented in 6 of 65 (9.2%) thigh injections but only in 1 of 93 (1.1%) abdominal injections. These data show that grade 2 ISRs were more common in the thigh compared with the abdomen possibly because the thigh contains lesser adipose tissue than the abdomen. Grade 2 ISRs resolved without any sequela within a median of 7 d. scBor administration on the abdomen instead of the thigh should be considered, especially for emaciated patients, because ISR rapidly resolves within the interval before the next injection even if it occurs.

Original languageEnglish
Pages (from-to)157-161
Number of pages5
JournalEuropean Journal of Haematology
Volume90
Issue number2
DOIs
Publication statusPublished - Feb 2013

Fingerprint

Thigh
Abdomen
Injections
Incidence
Multiple Myeloma
Bortezomib
Irritants
Cytotoxins
Peripheral Nervous System Diseases
Intravenous Administration
Adipose Tissue

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Higher incidence of injection site reactions after subcutaneous bortezomib administration on the thigh compared with the abdomen. / Kamimura, Tomohiko; Miyamoto, Toshihiro; Yokota, Noriko; Takashima, Shuichiro; Jeong, Yong; Ito, Yoshikiyo; Akashi, Koichi.

In: European Journal of Haematology, Vol. 90, No. 2, 02.2013, p. 157-161.

Research output: Contribution to journalArticle

@article{c81635e139aa4dd8a9d8e192a0aa1855,
title = "Higher incidence of injection site reactions after subcutaneous bortezomib administration on the thigh compared with the abdomen",
abstract = "Subcutaneous (sc) rather than intravenous administration of bortezomib (Bor) is becoming more common for treating multiple myeloma (MM) because scBor results in lower incidence and severity of peripheral neuropathy and has equivalent efficacy. Bor is an irritant cytotoxic agent when it leaks out; therefore, it is recommended that injections of scBor should be rotated among eight different sites on the abdomen and thigh. However, detailed information about injection site reaction (ISR) has not been sufficiently documented. We retrospectively analyzed the incidence and severity of ISR following scBor administration in 15 Japanese patients with MM. Grade 1 ISR occurred following 40 of 158 (25.3{\%}) scBor injections in ten patients, whereas grade 2 ISRs occurred following seven injections (4.4{\%}) in five patients. Five patients did not develop ISR. Of note, grade 2 ISR was documented in 6 of 65 (9.2{\%}) thigh injections but only in 1 of 93 (1.1{\%}) abdominal injections. These data show that grade 2 ISRs were more common in the thigh compared with the abdomen possibly because the thigh contains lesser adipose tissue than the abdomen. Grade 2 ISRs resolved without any sequela within a median of 7 d. scBor administration on the abdomen instead of the thigh should be considered, especially for emaciated patients, because ISR rapidly resolves within the interval before the next injection even if it occurs.",
author = "Tomohiko Kamimura and Toshihiro Miyamoto and Noriko Yokota and Shuichiro Takashima and Yong Jeong and Yoshikiyo Ito and Koichi Akashi",
year = "2013",
month = "2",
doi = "10.1111/ejh.12055",
language = "English",
volume = "90",
pages = "157--161",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Higher incidence of injection site reactions after subcutaneous bortezomib administration on the thigh compared with the abdomen

AU - Kamimura, Tomohiko

AU - Miyamoto, Toshihiro

AU - Yokota, Noriko

AU - Takashima, Shuichiro

AU - Jeong, Yong

AU - Ito, Yoshikiyo

AU - Akashi, Koichi

PY - 2013/2

Y1 - 2013/2

N2 - Subcutaneous (sc) rather than intravenous administration of bortezomib (Bor) is becoming more common for treating multiple myeloma (MM) because scBor results in lower incidence and severity of peripheral neuropathy and has equivalent efficacy. Bor is an irritant cytotoxic agent when it leaks out; therefore, it is recommended that injections of scBor should be rotated among eight different sites on the abdomen and thigh. However, detailed information about injection site reaction (ISR) has not been sufficiently documented. We retrospectively analyzed the incidence and severity of ISR following scBor administration in 15 Japanese patients with MM. Grade 1 ISR occurred following 40 of 158 (25.3%) scBor injections in ten patients, whereas grade 2 ISRs occurred following seven injections (4.4%) in five patients. Five patients did not develop ISR. Of note, grade 2 ISR was documented in 6 of 65 (9.2%) thigh injections but only in 1 of 93 (1.1%) abdominal injections. These data show that grade 2 ISRs were more common in the thigh compared with the abdomen possibly because the thigh contains lesser adipose tissue than the abdomen. Grade 2 ISRs resolved without any sequela within a median of 7 d. scBor administration on the abdomen instead of the thigh should be considered, especially for emaciated patients, because ISR rapidly resolves within the interval before the next injection even if it occurs.

AB - Subcutaneous (sc) rather than intravenous administration of bortezomib (Bor) is becoming more common for treating multiple myeloma (MM) because scBor results in lower incidence and severity of peripheral neuropathy and has equivalent efficacy. Bor is an irritant cytotoxic agent when it leaks out; therefore, it is recommended that injections of scBor should be rotated among eight different sites on the abdomen and thigh. However, detailed information about injection site reaction (ISR) has not been sufficiently documented. We retrospectively analyzed the incidence and severity of ISR following scBor administration in 15 Japanese patients with MM. Grade 1 ISR occurred following 40 of 158 (25.3%) scBor injections in ten patients, whereas grade 2 ISRs occurred following seven injections (4.4%) in five patients. Five patients did not develop ISR. Of note, grade 2 ISR was documented in 6 of 65 (9.2%) thigh injections but only in 1 of 93 (1.1%) abdominal injections. These data show that grade 2 ISRs were more common in the thigh compared with the abdomen possibly because the thigh contains lesser adipose tissue than the abdomen. Grade 2 ISRs resolved without any sequela within a median of 7 d. scBor administration on the abdomen instead of the thigh should be considered, especially for emaciated patients, because ISR rapidly resolves within the interval before the next injection even if it occurs.

UR - http://www.scopus.com/inward/record.url?scp=84872781052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872781052&partnerID=8YFLogxK

U2 - 10.1111/ejh.12055

DO - 10.1111/ejh.12055

M3 - Article

C2 - 23240903

AN - SCOPUS:84872781052

VL - 90

SP - 157

EP - 161

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 2

ER -